Lack of effect of chloroquine on the debrisoquine (CYP2D6) and S-mephenytoin (CYP2C19) hydroxylation phenotypes

British Journal of Clinical Pharmacology

Volumn 41, Issue 4, 1996, Pages 344-346

  Masimirembwa, Collen M ^a   Gustafsson, Lars L ^b   Dahl, Marja Liisa ^b   Abdi, Yakoub Aden ^b   Hasler, Julia A ^c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF ZIMBABWE   (Zimbabwe)

Author keywords

Chloroquine; Debrisoquine hydroxylase; Phenotyping; S mephenytoin hydroxylase

Indexed keywords

4 HYDROXYDEBRISOQUINE; CHLOROQUINE; CYTOCHROME P450; DEBRISOQUINE; MEPHENYTOIN;

ADULT; ARTICLE; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG URINE LEVEL; ENANTIOMER; ENZYME ACTIVITY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PHENOTYPE; PRIORITY JOURNAL; STEREOSPECIFICITY; VOLUNTEER;

EID: 0029917326     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1996.30713.x     Document Type: Article

References (12)

1. Kalow W, Bertilsson L. Interethnic factors affecting drug response. Adv Drug Rev 1994; 25: 1-53.
2. Lennard MS, Iyun AO, Jackson PR, Tucker GT, Woods HF. Evidence for dissociation in the control of sparteine, debrisoquine and metoprolol metabolism in Nigerians. Pharmacogenetics 1992; 2: 89-92.
3. Iyun AO, Tucker GT, Woods HF, Lennard MS. The 4-hydroxylation of S-mephenytoin in Nigerians: A population study. Microsomes and drug oxidations - VIIIth International Symposium, eds Ingelman-Sundberg, M, Gustafsson J-A, Orrenius S. Stockholm. Abstr 373.
4. Masimirembwa CM, Bertilsson L, Hasler JA, Johansson I, Ingelman-Sundberg M. Genotyping and phenotyping of mephenytoin hydroxylase (CYP2C19) in the Shona population of Zimbabwe. Clin Pharmacol Ther 1995; 57: 651-61.
5. Brosen K, Gram LF, Haghfelt T, Bertilsson L. Extensive metabolisers of debrisoquine become poor metabolisers during quinidine treatment. Pharmacol Toxicol 1987; 60: 312-314.
6. Lancaster DL, Adio RA, Tai KK, et al. Inhibition of metoprolol metabolism by chloroquine and other antimalarial drugs. J Pharm Pharmacol 1990; 42: 267-271.
7. Masimirembwa CM, Hasler JA, Johansson I. Inhibitory effects of antiparasitic drugs on cytochrome P4502D6. Eur J Clin Pharmacol 1995; 48: 35-38.
8. Alvan G, Ekman L, Lindström B. Determination of chloroquine and its desethyl metabolite in plasma, red blood cells and urine by liquid chromatography. J Chromatogr 1982; 229: 241-247.
9. Sanz EJ, Villen T, Alm C, Bertilsson L. S-mephenytoin hydroxylation phenotype in a Swedish population determined after coadministration with debrisoquin. Clin Pharmacol Ther 1989; 45: 495-499.
10. Lennard MS, Silas JH, Smith AJ, Tucker GT. Determination of debrisoquine and its 4-hydroxymetabolite in biological fluids by gas chromatography with flameionization and nitrogen-selective detection. J Chromatogr 1977; 133: 161-166.
11. Wedlund PJ, Sweetman BJ, McAllister CB, Branch RA, Wilkinson GR. Direct enantiomer resolution of mephenytoin and its N-demethylated metabolite in plasma and blood using chiral capillary gas chromatigraphy. J Chromatogr 1984; 307: 121-127.
12. Prouty RW, Kuroda K. Spectrophotometric determination and distribution of chloroquine in human tissues. J Lab Clin Med 1958; 52: 477-480.